코어 임상 분자진단 시장 : 제품 유형별, 기술별, 용도별 - 세계 기회 분석과 산업 예측(2023-2032년)

Core Clinical Molecular Diagnostics Market By Product type, By Technique (PCR, Nucleic Acid Sequencing, Fluorescence In Situ Hybridization, Others), By Application : Global Opportunity Analysis and Industry Forecast, 2023-2032

US $ 5,730 ￦ 8,053,000

PDF (Business License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 5회 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 2명 이상이 이용할 경우, 추가 요금을 지불하여 라이선스 업그레이드로 최대 5명까지 이용 가능합니다.

US $ 9,600 ￦ 13,492,000

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

PDF 보고서 및 Excel 데이터를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 보고서 업데이트 서비스가 무료로 제공됩니다.

한글목차

코어 임상 분자진단 시장은 2022년에 48억 달러로 평가되며, 2023-2032년의 CAGR은 9.50%를 보이며, 2032년에는 119억 달러에 달할 것으로 추정됩니다.

코어 임상 분자진단은 의료 실험실에서 수행되는 필수 기술 및 절차를 의미합니다. 분자 수준에서 유전 물질(DNA, RNA) 및 단백질 분석에 중점을 두어 질병을 진단하고 치료 방침을 결정하는 데 도움을 줍니다. 이러한 진단 방법에는 중합효소연쇄반응(PCR), DNA 시퀀싱, 차세대 시퀀싱(NGS), 형광 현장 혼성화(FISH), 면역조직화학(IHC) 등 다양한 기법이 포함됩니다. 코어 임상 분자진단학은 유전자 변이, 감염 요인, 질병과 관련된 바이오마커를 식별하여 환자 맞춤형 치료를 가능하게 하고 임상 결과를 개선하는 맞춤의료에서 중요한 역할을 하고 있습니다.

질병의 확산과 인구의 고령화는 임상 분자진단 의약품에 대한 수요 증가의 큰 원동력이 되고 있습니다. 인구 고령화에 따라 암, 심혈관 질환, 신경퇴행성 질환 등 만성질환 및 노화 관련 질환의 발병률이 크게 증가합니다. 또한 고령화로 인해 면역력이 저하되어 감염성 질환에 걸리기 쉬워집니다. 미국 인구 조사국에서 입수한 데이터에 따르면 2021년 미국 노인 인구는 전체 인구의 16.5%인 5,400만 명에 달할 것으로 예상됩니다. 또한 이 수치는 2050년까지 8,570만 명으로 증가할 것으로 예상됩니다. 또한 미국 국립암연구소에 따르면 유방암 진단 연령의 중앙값은 61세, 대장암 68세, 폐암 70세, 전립선암 66세입니다.

따라서 임상 분자진단학은 특정 질병과 관련된 유전자 변이, 감염 인자 및 바이오마커를 식별하여 이러한 질병을 정확하게 진단하는 데 중요한 역할을 합니다. 정확하고 시기적절한 진단 정보를 제공하는 능력은 의료 서비스 프로바이더가 맞춤 치료 전략을 시행할 수 있도록 하여 환자의 결과를 개선하고 고령화 사회에서 보다 효과적인 질병 관리에 기여할 수 있습니다. 이처럼 코어 임상 분자진단에 대한 수요는 전 세계 고령화 사회의 의료 수요를 충족시키기 위해 앞으로도 계속 증가할 것으로 예상됩니다.

또한 헬스케어에 대한 지출 증가는 코어 임상 분자진단 시장의 성장을 가속하는 중요한 요인으로 작용하고 있습니다. 전 세계에서 의료비 지출이 증가함에 따라 환자 치료와 결과를 개선하기 위한 진단 능력 향상에 대한 중요성이 커지고 있습니다. 정밀하고 개인화된 진단 정보를 제공하는 임상 핵심 분자진단의 능력은 정밀의료에 대한 관심이 높아지는 추세와 잘 맞아떨어집니다. 헬스케어에 더 많은 자원이 할당되면서 PCR, DNA 시퀀싱, NGS와 같은 첨단 진단 기술에 투자할 수 있는 능력과 의지가 높아지면서 시장 성장을 주도하고 있습니다. 또한 의료 시스템이 자원 활용을 최적화하고 비용 효율성을 개선하기 위해 노력함에 따라 코어 임상 분자진단이 제공하는 효율성과 정확성이 점점 더 매력적으로 다가오면서 시장 확대를 더욱 촉진하고 있습니다.

코어 임상 분자진단 시장은 제품 유형, 기술, 용도, 지역별로 세분화됩니다. 제품 유형에 따라 시장은 기기, 시약, 소프트웨어 및 서비스로 분류됩니다. 기술별로 시장은 PCR, 핵산 시퀀싱, 형광 in situ hybridization(FISH), 기타로 분류됩니다. 애플리케이션별로 시장은 감염성 질환, 유전자 질환, 암 검진, 기타로 분류됩니다. 지역별로는 북미(미국, 캐나다, 멕시코), 유럽(독일, 프랑스, 영국, 이탈리아, 스페인, 기타 유럽), 아시아태평양(중국, 일본, 인도, 호주, 한국, 기타 아시아태평양), LA(브라질, 콜롬비아, 아르헨티나, 기타 LA 지역)로 나뉩니다, MEA(GCC, 북아프리카, 기타 MEA 지역)로 분석됩니다.

이해관계자를 위한 주요 이점

• 이 보고서는 2022-2032년 코어 임상 분자진단 시장 분석 시장 부문, 현재 동향, 추정 및 동향, 역학에 대한 정량적 분석을 제공하여 코어 임상 분자진단 시장의 유력한 시장 기회를 식별합니다.
• 시장 성장 촉진요인, 시장 성장 억제요인, 시장 기회와 관련된 정보와 함께 시장 조사를 제공합니다.
• Porter's Five Forces 분석은 이해 관계자가 이익 중심의 비즈니스 결정을 내리고 공급자와 구매자의 네트워크를 강화할 수 있도록 구매자와 공급자의 잠재력을 밝힙니다.
• 코어 임상 분자진단 시장의 세분화를 자세히 분석하여 시장 기회를 파악할 수 있습니다.
• 각 지역의 주요 국가는 세계 시장에 대한 매출 기여도에 따라 매핑되어 있습니다.
• 시장 기업의 포지셔닝은 벤치마킹을 용이하게 하고 시장 기업의 현재 위치를 명확하게 이해할 수 있습니다.
• 이 보고서에는 지역별 및 세계 코어 임상 분자진단 의약품 시장 동향, 주요 기업, 시장 부문, 용도, 시장 성장 전략에 대한 분석이 포함되어 있습니다.

이 보고서는 사용자 정의가 가능합니다.

• 규제 가이드라인
• 고객의 관심사에 따른 기업 개요 추가
• 기업 개요 확장 리스트
• 과거 시장 데이터

목차

제1장 서론

제2장 주요 요약

제3장 시장 개요

• 시장의 정의와 범위
• 주요 조사 결과
  • 영향요인
  • 주요 투자 기회
• Porter's Five Forces 분석
• 시장 역학
  • 촉진요인
  • 억제요인
  • 기회

제4장 코어 임상 분자진단 시장 : 제품 유형별

• 개요
• 검사기기
• 시약
• 소프트웨어와 서비스

제5장 코어 임상 분자진단 시장 : 기술별

• 개요
• PCR법
• 핵산 배열 결정
• 형광 in situ 하이브리다이제이션(FISH)
• 기타

제6장 코어 임상 분자진단 시장 : 용도별

• 개요
• 감염증
• 유전자 질환
• 암스크리닝
• 기타

제7장 코어 임상 분자진단 시장 : 지역별

• 개요
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인
  • 기타
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 기타
• 라틴아메리카
  • 브라질
  • 콜롬비아
  • 아르헨티나
  • 기타 라틴아메리카
• 중동 및 아프리카
  • Gcc
  • 남아프리카공화국
  • 북아프리카
  • 기타

제8장 경쟁 상황

• 서론
• 주요 성공 전략
• 주요 10사의 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝, 2022년

제9장 기업 개요

• F. Hoffmann La Roche
• Novartis AG
• Abbott Laboratories
• Becton Dickinson & Company
• Siemens Healthineers AG
• Agilent Technologies, Inc.
• Hologic, Inc.
• BioMerieux SA
• Qiagen NV.
• cepheid ab

KSA

영문 목차

영문목차

The core clinical molecular diagnostics market was valued at $4.8 billion in 2022 and is estimated to reach $11.9 billion by 2032, exhibiting a CAGR of 9.50% from 2023 to 2032. Core clinical molecular diagnostics refer to essential techniques and procedures conducted in medical laboratories. They focus on analyzing genetic material (DNA, RNA) and proteins at the molecular level to diagnose diseases and guide treatment decisions. These diagnostics encompass various methodologies such as Polymerase Chain Reaction (PCR), DNA sequencing, Next-Generation Sequencing (NGS), Fluorescence In Situ Hybridization (FISH), and immunohistochemistry (IHC). Core clinical molecular diagnostics play a crucial role in personalized medicine by identifying genetic variations, infectious agents, and biomarkers associated with diseases, enabling tailored patient care and improving clinical outcomes.

The increasing prevalence of diseases and the aging population are major driving forces behind the growing demand for core clinical molecular diagnostics. As populations age, the incidence of chronic and age-related diseases such as cancer, cardiovascular diseases, and neurodegenerative disorders rises significantly. Additionally, the aging demographic is more susceptible to infectious diseases due to weakened immune systems. According to data obtained from the U.S. Census Bureau, in 2021, elderly population in the U.S. accounted for 16.5% of the total population, which is 54 million. Moreover, this number is anticipated to increase to 85.7 million by 2050. In addition, according to the National Cancer Institute, the median age for diagnosis is 61 years for breast cancer, 68 years for colorectal cancer, 70 years for lung cancer, and 66 years for prostate cancer.

Thus, clinical molecular diagnostics play a critical role in accurately diagnosing these conditions by identifying genetic variations, infectious agents, and biomarkers associated with specific diseases. Their ability to provide precise and timely diagnostic information enables healthcare providers to implement personalized treatment strategies, improving patient outcomes and contributing to more effective disease management in an aging population. As such, the demand for core clinical molecular diagnostics is expected to continue increasing to meet the healthcare needs of aging populations worldwide.

In addition, the rising expenditure in healthcare is indeed a significant driver propelling the growth of the core clinical molecular diagnostics market. As healthcare spending increases globally, there's a greater emphasis on improving diagnostic capabilities to enhance patient care and outcomes. The ability of clinical core molecular diagnostics offers precise and personalized diagnostic information, which aligns well with the growing trend towards precision medicine. With more resources being allocated to healthcare, there's an increased ability and willingness to invest in advanced diagnostic technologies such as PCR, DNA sequencing, and NGS, driving market growth. Additionally, as healthcare systems strive to optimize resource utilization and improve cost-effectiveness, the efficiency and accuracy offered by core clinical molecular diagnostics become increasingly attractive, further fueling market expansion.

The core clinical molecular diagnostics market is segmented on the basis of product type, technique, application, and region. On the basis of product type, the market is segmented into Instruments, reagents and software & services. On the basis of technique, the market is segmented into PCR, nucleic acid sequencing, fluorescence in situ hybridization (FISH), and others. On the basis of application, the market is segmented into infectious diseases, genetic disorders, cancer screening, and others. Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LA (Brazil, Colombia, Argentina, and rest of LA) and MEA (GCC, South Africa, North Africa and rest of MEA).

The major key players that operate in the core clinical molecular diagnostics market are F. Hoffmann-La Roche Ltd., Novartis, Abbott Laboratories, Becton, Dickinson and Company, Siemens Healthineers, Agilent Technologies, Hologic, Inc. Bio-Rad Laboratories, Inc., Qiagen and bioMerieux. The key players have adopted product launch, product development and product approval as the key strategy to expand their product portfolio.

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the core clinical molecular diagnostics market analysis from 2022 to 2032 to identify the prevailing core clinical molecular diagnostics market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the core clinical molecular diagnostics market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global core clinical molecular diagnostics market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Regulatory Guidelines
• Additional company profiles with specific to client's interest
• Expanded list for Company Profiles
• Historic market data

Key Market Segments

By Product type

• Instruments
• Reagents
• Software and Services

By Technique

• PCR
• Nucleic Acid Sequencing
• Fluorescence In Situ Hybridization (FISH)
• Others

By Application

• Infectious Disease
• Genetic disorder
• Cancer Screening
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Colombia
  • Argentina
  • Rest Of La
• Middle East and Africa
  • Gcc
  • South Africa
  • North Africa
  • Rest Of Mea

Key Market Players:

• F. Hoffmann La Roche
• Novartis AG
• Abbott Laboratories
• Becton Dickinson & Company
• Siemens Healthineers AG
• Agilent Technologies, Inc.
• Hologic, Inc.
• BioMerieux SA
• Qiagen NV.
• cepheid ab

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
• 3.4. Market dynamics
  • 3.4.1. Drivers
  • 3.4.2. Restraints
  • 3.4.3. Opportunities

CHAPTER 4: CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Instruments
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. Reagents
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country
• 4.4. Software and Services
  • 4.4.1. Key market trends, growth factors and opportunities
  • 4.4.2. Market size and forecast, by region
  • 4.4.3. Market share analysis by country

CHAPTER 5: CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. PCR
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Nucleic Acid Sequencing
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country
• 5.4. Fluorescence In Situ Hybridization (FISH)
  • 5.4.1. Key market trends, growth factors and opportunities
  • 5.4.2. Market size and forecast, by region
  • 5.4.3. Market share analysis by country
• 5.5. Others
  • 5.5.1. Key market trends, growth factors and opportunities
  • 5.5.2. Market size and forecast, by region
  • 5.5.3. Market share analysis by country

CHAPTER 6: CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Infectious Disease
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
• 6.3. Genetic disorder
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country
• 6.4. Cancer Screening
  • 6.4.1. Key market trends, growth factors and opportunities
  • 6.4.2. Market size and forecast, by region
  • 6.4.3. Market share analysis by country
• 6.5. Others
  • 6.5.1. Key market trends, growth factors and opportunities
  • 6.5.2. Market size and forecast, by region
  • 6.5.3. Market share analysis by country

CHAPTER 7: CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY REGION

• 7.1. Overview
  • 7.1.1. Market size and forecast By Region
• 7.2. North America
  • 7.2.1. Key market trends, growth factors and opportunities
  • 7.2.2. Market size and forecast, by Product type
  • 7.2.3. Market size and forecast, by Technique
  • 7.2.4. Market size and forecast, by Application
  • 7.2.5. Market size and forecast, by country
    • 7.2.5.1. U.S.
    • 7.2.5.1.1. Market size and forecast, by Product type
    • 7.2.5.1.2. Market size and forecast, by Technique
    • 7.2.5.1.3. Market size and forecast, by Application
    • 7.2.5.2. Canada
    • 7.2.5.2.1. Market size and forecast, by Product type
    • 7.2.5.2.2. Market size and forecast, by Technique
    • 7.2.5.2.3. Market size and forecast, by Application
    • 7.2.5.3. Mexico
    • 7.2.5.3.1. Market size and forecast, by Product type
    • 7.2.5.3.2. Market size and forecast, by Technique
    • 7.2.5.3.3. Market size and forecast, by Application
• 7.3. Europe
  • 7.3.1. Key market trends, growth factors and opportunities
  • 7.3.2. Market size and forecast, by Product type
  • 7.3.3. Market size and forecast, by Technique
  • 7.3.4. Market size and forecast, by Application
  • 7.3.5. Market size and forecast, by country
    • 7.3.5.1. Germany
    • 7.3.5.1.1. Market size and forecast, by Product type
    • 7.3.5.1.2. Market size and forecast, by Technique
    • 7.3.5.1.3. Market size and forecast, by Application
    • 7.3.5.2. France
    • 7.3.5.2.1. Market size and forecast, by Product type
    • 7.3.5.2.2. Market size and forecast, by Technique
    • 7.3.5.2.3. Market size and forecast, by Application
    • 7.3.5.3. UK
    • 7.3.5.3.1. Market size and forecast, by Product type
    • 7.3.5.3.2. Market size and forecast, by Technique
    • 7.3.5.3.3. Market size and forecast, by Application
    • 7.3.5.4. Italy
    • 7.3.5.4.1. Market size and forecast, by Product type
    • 7.3.5.4.2. Market size and forecast, by Technique
    • 7.3.5.4.3. Market size and forecast, by Application
    • 7.3.5.5. Spain
    • 7.3.5.5.1. Market size and forecast, by Product type
    • 7.3.5.5.2. Market size and forecast, by Technique
    • 7.3.5.5.3. Market size and forecast, by Application
    • 7.3.5.6. Rest of Europe
    • 7.3.5.6.1. Market size and forecast, by Product type
    • 7.3.5.6.2. Market size and forecast, by Technique
    • 7.3.5.6.3. Market size and forecast, by Application
• 7.4. Asia-Pacific
  • 7.4.1. Key market trends, growth factors and opportunities
  • 7.4.2. Market size and forecast, by Product type
  • 7.4.3. Market size and forecast, by Technique
  • 7.4.4. Market size and forecast, by Application
  • 7.4.5. Market size and forecast, by country
    • 7.4.5.1. Japan
    • 7.4.5.1.1. Market size and forecast, by Product type
    • 7.4.5.1.2. Market size and forecast, by Technique
    • 7.4.5.1.3. Market size and forecast, by Application
    • 7.4.5.2. China
    • 7.4.5.2.1. Market size and forecast, by Product type
    • 7.4.5.2.2. Market size and forecast, by Technique
    • 7.4.5.2.3. Market size and forecast, by Application
    • 7.4.5.3. India
    • 7.4.5.3.1. Market size and forecast, by Product type
    • 7.4.5.3.2. Market size and forecast, by Technique
    • 7.4.5.3.3. Market size and forecast, by Application
    • 7.4.5.4. Australia
    • 7.4.5.4.1. Market size and forecast, by Product type
    • 7.4.5.4.2. Market size and forecast, by Technique
    • 7.4.5.4.3. Market size and forecast, by Application
    • 7.4.5.5. South Korea
    • 7.4.5.5.1. Market size and forecast, by Product type
    • 7.4.5.5.2. Market size and forecast, by Technique
    • 7.4.5.5.3. Market size and forecast, by Application
    • 7.4.5.6. Rest of Asia-Pacific
    • 7.4.5.6.1. Market size and forecast, by Product type
    • 7.4.5.6.2. Market size and forecast, by Technique
    • 7.4.5.6.3. Market size and forecast, by Application
• 7.5. Latin America
  • 7.5.1. Key market trends, growth factors and opportunities
  • 7.5.2. Market size and forecast, by Product type
  • 7.5.3. Market size and forecast, by Technique
  • 7.5.4. Market size and forecast, by Application
  • 7.5.5. Market size and forecast, by country
    • 7.5.5.1. Brazil
    • 7.5.5.1.1. Market size and forecast, by Product type
    • 7.5.5.1.2. Market size and forecast, by Technique
    • 7.5.5.1.3. Market size and forecast, by Application
    • 7.5.5.2. Colombia
    • 7.5.5.2.1. Market size and forecast, by Product type
    • 7.5.5.2.2. Market size and forecast, by Technique
    • 7.5.5.2.3. Market size and forecast, by Application
    • 7.5.5.3. Argentina
    • 7.5.5.3.1. Market size and forecast, by Product type
    • 7.5.5.3.2. Market size and forecast, by Technique
    • 7.5.5.3.3. Market size and forecast, by Application
    • 7.5.5.4. Rest Of La
    • 7.5.5.4.1. Market size and forecast, by Product type
    • 7.5.5.4.2. Market size and forecast, by Technique
    • 7.5.5.4.3. Market size and forecast, by Application
• 7.6. Middle East and Africa
  • 7.6.1. Key market trends, growth factors and opportunities
  • 7.6.2. Market size and forecast, by Product type
  • 7.6.3. Market size and forecast, by Technique
  • 7.6.4. Market size and forecast, by Application
  • 7.6.5. Market size and forecast, by country
    • 7.6.5.1. Gcc
    • 7.6.5.1.1. Market size and forecast, by Product type
    • 7.6.5.1.2. Market size and forecast, by Technique
    • 7.6.5.1.3. Market size and forecast, by Application
    • 7.6.5.2. South Africa
    • 7.6.5.2.1. Market size and forecast, by Product type
    • 7.6.5.2.2. Market size and forecast, by Technique
    • 7.6.5.2.3. Market size and forecast, by Application
    • 7.6.5.3. North Africa
    • 7.6.5.3.1. Market size and forecast, by Product type
    • 7.6.5.3.2. Market size and forecast, by Technique
    • 7.6.5.3.3. Market size and forecast, by Application
    • 7.6.5.4. Rest Of Mea
    • 7.6.5.4.1. Market size and forecast, by Product type
    • 7.6.5.4.2. Market size and forecast, by Technique
    • 7.6.5.4.3. Market size and forecast, by Application

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product mapping of top 10 player
• 8.4. Competitive dashboard
• 8.5. Competitive heatmap
• 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

• 9.1. F. Hoffmann La Roche
  • 9.1.1. Company overview
  • 9.1.2. Key executives
  • 9.1.3. Company snapshot
  • 9.1.4. Operating business segments
  • 9.1.5. Product portfolio
  • 9.1.6. Business performance
  • 9.1.7. Key strategic moves and developments
• 9.2. Novartis AG
  • 9.2.1. Company overview
  • 9.2.2. Key executives
  • 9.2.3. Company snapshot
  • 9.2.4. Operating business segments
  • 9.2.5. Product portfolio
  • 9.2.6. Business performance
  • 9.2.7. Key strategic moves and developments
• 9.3. Abbott Laboratories
  • 9.3.1. Company overview
  • 9.3.2. Key executives
  • 9.3.3. Company snapshot
  • 9.3.4. Operating business segments
  • 9.3.5. Product portfolio
  • 9.3.6. Business performance
  • 9.3.7. Key strategic moves and developments
• 9.4. Becton Dickinson & Company
  • 9.4.1. Company overview
  • 9.4.2. Key executives
  • 9.4.3. Company snapshot
  • 9.4.4. Operating business segments
  • 9.4.5. Product portfolio
  • 9.4.6. Business performance
  • 9.4.7. Key strategic moves and developments
• 9.5. Siemens Healthineers AG
  • 9.5.1. Company overview
  • 9.5.2. Key executives
  • 9.5.3. Company snapshot
  • 9.5.4. Operating business segments
  • 9.5.5. Product portfolio
  • 9.5.6. Business performance
  • 9.5.7. Key strategic moves and developments
• 9.6. Agilent Technologies, Inc.
  • 9.6.1. Company overview
  • 9.6.2. Key executives
  • 9.6.3. Company snapshot
  • 9.6.4. Operating business segments
  • 9.6.5. Product portfolio
  • 9.6.6. Business performance
  • 9.6.7. Key strategic moves and developments
• 9.7. Hologic, Inc.
  • 9.7.1. Company overview
  • 9.7.2. Key executives
  • 9.7.3. Company snapshot
  • 9.7.4. Operating business segments
  • 9.7.5. Product portfolio
  • 9.7.6. Business performance
  • 9.7.7. Key strategic moves and developments
• 9.8. BioMerieux SA
  • 9.8.1. Company overview
  • 9.8.2. Key executives
  • 9.8.3. Company snapshot
  • 9.8.4. Operating business segments
  • 9.8.5. Product portfolio
  • 9.8.6. Business performance
  • 9.8.7. Key strategic moves and developments
• 9.9. Qiagen NV.
  • 9.9.1. Company overview
  • 9.9.2. Key executives
  • 9.9.3. Company snapshot
  • 9.9.4. Operating business segments
  • 9.9.5. Product portfolio
  • 9.9.6. Business performance
  • 9.9.7. Key strategic moves and developments
• 9.10. cepheid ab
  • 9.10.1. Company overview
  • 9.10.2. Key executives
  • 9.10.3. Company snapshot
  • 9.10.4. Operating business segments
  • 9.10.5. Product portfolio
  • 9.10.6. Business performance
  • 9.10.7. Key strategic moves and developments

관련자료